Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) shares were up 6.2% during mid-day trading on Friday. The company traded as high as $9.36 and last traded at $9.31. 42,500 shares were traded during mid-day trading, a decline of 69% from the average daily volume of 138,779 shares. The stock had previously closed at $8.77.
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Two analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR presently has a consensus rating of “Buy”.
Check Out Our Latest Stock Report on Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co., Ltd. Unsponsored ADR Stock Up 1.3%
The stock has a market capitalization of $15.74 billion, a P/E ratio of 9.25, a P/E/G ratio of 3.14 and a beta of 0.08. The company has a current ratio of 1.14, a quick ratio of 1.00 and a debt-to-equity ratio of 0.01. The firm’s fifty day moving average is $9.06 and its 200-day moving average is $9.27.
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.18. The firm had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. As a group, equities research analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current year.
Shionogi & Co., Ltd. Unsponsored ADR Company Profile
Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.
Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.
Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.
Further Reading
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
- Palantir’s Potential Next Catalyst After Retail Profit-Taking
- Morgan Stanley Beats on Earnings, But Shares Fall on Trading Mix
- RTX Locks In a Decade of Defense Dominance
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
